



OPEN ACCESS

SUPPLEMENTARY DATA

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization

Nishant SAXENA*¹, Shashank P. KATIYAR†¹, Ye LIU*, Abhinav GROVER†, Ran GAO*, Durai SUNDAR†², Sunil C. KAUL*² and Renu WADHWA*²

*National Institute of Advanced Industrial Science and Technology (AIST), Central 4, 1-1-1 Higashi, Tsukuba Science City 305-8562, Japan, and †Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology (IIT) Delhi, Hauz Khas, New Delhi 110016, India

Table S1 Predicted amino acid residues of proteins that participate in docking

Mortalin	Bcl-2	Bcl-xL
320–400	12–29, 87–103, 113–119, 215–last	8–21, 135–149, 145–170, 216–last

Table S2 List of functional residues at the interface of mortalin, Bcl-2 and Bcl-xL proteins

Protein	Residues
Mortalin	Val-373, Gly-376, Asp-377, Asp-380, Val-381, Leu-382, Leu-383, Leu-384, Val-386, Thr-387
Bcl-2	Ser-116, Cys-229, Val-92, Leu-95, Gln-118, Val-226, Ala-113
Bcl-xL	Tyr-15, Ser-18, Gln-19, Gly-21, Trp-213, Phe-214, Thr-216, Leu-226, Leu-229, Phe-230

Table S3 Interfacial residues in docked protein–protein complexes before MD simulations

Mortalin–Bcl-2 Complex		Mortalin–Bcl-xL Complex	
Mortalin	Bcl-2	Mortalin	Bcl-xL
Asp-145, Arg-148, Glu-182, Asp-318, Glu-320, Pro-411, Thr-412, Lys-413, Lys-481, Lys-483, Gly-486, Glu-488	Arg-109, Arg-110, Ala-113, Glu-114, Ser-117, Gln-118, His-120, Arg-164, Pro-208, Phe-212, Leu-215, Ser-216, Thr-219, Leu-220, Ala-224, Leu-225, Val-226, Gly-227, Ala-228, Cys-229, Gly-233, Ala-234, Tyr-235, Leu-236, His-238, Lys-239	Thr-379, Asp-380, Val-381, Leu-382, Leu-383, Leu-384, Asp-385, Gln-463, Glu-465, Asp-469, Asp-471, Ala-472, Asn-473	Trp-181, Asn-185, Gly-186, Asp-189, Thr-190, Glu-193, Leu-194, Tyr-195

¹ These authors contributed equally to this work.

² Correspondence may be addressed to either of these authors (email renu-wadhwa@aist.go.jp or s-kaul@aist.go.jp or sundar@dbeb.iitd.ac.in).

**Table S4 Interfacial residues in docked protein–protein complexes after MD simulations**

Mortalin-Bcl-2 complex		Mortalin-Bcl-xL complex	
Mortalin	Bcl-2	Mortalin	Bcl-xL
Arg-148, Lys-152, Glu-202, Gln-204, Lys-205, Gly-206, Val-207, Phe-208, Glu-209, Val-210, Lys-211, Val-378, Thr-379, Asp-380, Val-381, Leu-382, Leu-383, Leu-384, Asp-385	Arg-110, Glu-114, Ser-117, Gln-118, His-120, Arg-164, Glu-165, Leu-223, Val-226, Gly-237, His-238, His-239	Gln-204, Lys-205, Gly-206, Val-207, Phe-208, Glu-209, Leu-403, Ile-404, Asn-405, Arg-406, Asn-407, Thr-408, Pro-411, Thr-412, Lys-413, Lys-414, Ser-415, Gln-416, Val-417, Phe-418, Asp-471, Ala-472, Asn-473	Trp-181, Glu-184, Asn-185, Gly-186, Asp-189, Thr-190, Glu-193, Leu-194, Tyr-195

Table S5 H-bond occupancy of mortalin–Bcl-2 complex during MD simulation Stable H-bonds with high occupancy are shown in bold letters.

Mortalin	Bcl-2	Occupancy
Gln-204-side	Ser-117-side	42.28%
Val-381-main	Val-226-main	1.15%
Asp-380-side	Arg-110-side	100.00%
Glu-202-side	Ser-117-side	69.08%
Glu-320-side	Arg-164-side	37.97%
Val-210-main	Gln-118-side	11.60%
Asp-385-side	Lys-239-side	34.47%
Lys-205-main	Glu-114-side	6.62%
Gly-206-main	Glu-114-side	25.60%
Glu-182-side	Arg-109-side	1.25%
Lys-413-side	Leu-215-main	5.94%
Glu-209-side	Tyr-235-main	0.72%
Asp-380-side	Ala-228-main	2.83%
Glu-320-side	His-120-side	1.34%
Glu-209-side	Gln-118-side	8.15%
Glu-209-side	Ala-234-main	32.89%
Asp-380-main	Hie-238-side	0.10%
Val-207-main	Glu-114-side	7.19%
Lys-413-side	Thr-219-side	0.05%
Asp-380-side	Cys-229-side	0.05%
Thr-379-side	Arg-110-side	0.38%
Lys-481-side	Asp-211-side	1.01%
Thr-379-side	Arg-110-side	0.14%
Val-210-main	Tyr-235-side	2.25%

Table S6 H-bond occupancy of mortalin–Bcl-xL complex during MD simulation Stable H-bonds with high occupancy are shown in bold letters.

Mortalin	Bcl-xL	Occupancy
Lys-481-side	Glu-202-side	34.52%
Lys-483-side	Glu-193-side	0.96%
Glu-488-side	Arg-204-side	100.00%
Asp-471-side	Arg-212-side	100.00%
Lys-483-side	Glu-193-main	0.62%
Asn-405-side	Asp-133-side	5.32%
Asp-380-side	Arg-212-side	0.62%
Asp-380-side	Trp-213-main	8.44%
Ser-415-main	Asn-136-side	3.79%
Asp-385-side	Ser-231-side	2.73%
Gln-463-side	Thr-190-side	1.25%
Lys-414-side	Asn-136-side	0.14%
Val-417-main	Asn-185-side	8.34%
Asp-385-side	Gly-227-main	20.13%
Lys-414-side	Asp-133-side	25.60%
Gln-463-side	Thr-190-side	5.80%
Asn-405-side	Lys-233-side	0.24%
Asn-473-side	Arg-212-side	2.73%
Asp-385-side	Ser-231-main	4.46%
Asn-407-side	Lys-233-side	1.34%
Arg-406-main	Lys-233-side	6.57%
Gln-463-side	Asn-185-main	1.73%
Gln-416-side	Trp-181-side	0.14%
Arg-209-side	Asp-179-main	0.05%
Gln-463-side	Asp-189-side	0.91%
Asn-407-side	Ser-231-side	0.05%
Lys-483-side	Thr-190-side	3.88%
Arg-209-side	Glu-182-side	67.02%
Lys-481-side	Glu-193-side	18.98%
Lys-483-side	Thr-190-main	0.14%
Gln-416-side	Glu-184-side	0.10%
Arg-209-side	Lys-180-main	0.43%
Gln-463-side	Glu-184-main	0.10%
Gln-463-side	Glu-184-side	0.05%
Glu-465-side	Asn-185-side	0.14%
Lys-483-side	Asn-185-main	0.91%
Lys-413-side	Thr-219-side	0.34%
His-536-side	Glu-184-side	33.27%
Glu-543-side	Gln-183-side	0.24%
Lys-413-side	Phe-214-main	0.14%

Received 25 March 2013/28 May 2013; accepted 3 June 2013

Published as Immediate Publication 20 September 2013, doi 10.1042/BSR20130034